The second National Institutes of Health International Congress on advances in uterine leiomyoma research: conference summary and future recommendations

Fertility and Sterility

Volumn 86, Issue 4, 2006, Pages 800-806

  Dixon, Darlene ^a   Parrott, Estella C ^b   Segars, James H ^b   Olden, Kenneth ^a   Pinn, Vivian W ^c  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

clinical treatment; clinical basic studies; fibroid; NIH conference summary; research recommendations; uterine leiomyoma

Indexed keywords

ASOPRISNIL; COLLAGEN; MIFEPRISTONE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER RESEARCH; CANCER THERAPY; CARCINOGENESIS; CLINICAL TRIAL; COLLAGEN SYNTHESIS; ESTROGEN SYNTHESIS; FAMILIAL CANCER; FUTUROLOGY; GENETIC LINKAGE; HEREDITARY LEIOMYOMATOSIS RENAL CELL CARCINOMA; HUMAN; HYSTERECTOMY; MEDICAL SOCIETY; MOLECULAR GENETICS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROFESSIONAL DELEGATION; QUALITY OF LIFE; SIDE EFFECT; SIGNAL TRANSDUCTION; UTERUS MYOMA;

ANIMALS; BIOMEDICAL RESEARCH; CLINICAL TRIALS; FEMALE; FORECASTING; HUMANS; LEIOMYOMA; NATIONAL INSTITUTES OF HEALTH (U.S.); RESEARCH; UNITED STATES; UTERINE NEOPLASMS;

EID: 33749251436     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2006.02.116     Document Type: Article

References (32)

1. Flake G.P., Andersen J., and Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 111 (2003) 1037-1054
2. Stewart E.A. Uterine fibroids. Lancet 357 (2001) 293-298
3. Vollenhoven B. Introduction: the epidemiology of uterine leiomyomas. Baillieres Clin Obstet Gynaecol 12 (1998) 169-176
4. Gambone J.C., and Reiter R.C. Hysterectomy: improving the patient's decision-making process. Clin Obstet Gynecol 40 (1997) 868-877
5. Cramer S.F., and Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 94 (1990) 435-438
6. Faerstein E., Szklo M., and Rosenshein N. Risk factors for uterine leiomyoma: a practice-based case-control study. I. African-American heritage, reproductive history, body size, and smoking. Am J Epidemiol 153 (2001) 1-10
7. Marshall L.M., Spiegelman D., Barbieri R.L., Goldman M.B., Manson J.E., Colditz G.A., et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 90 (1997) 967-973
8. Coronado G.D., Marshall L.M., and Schwartz S.M. Complications in pregnancy, labor, and delivery with uterine leiomyomas: a population-based study. Obstet Gynecol 95 (2000) 764-769
9. Marino J.L., Eskenazi B., Warner M., Samuels S., Vercellini P., Gavoni N., et al. Uterine leiomyoma and menstrual cycle characteristics in a population-based cohort study. Hum Reprod 19 (2004) 2350-2355
10. Robboy S.J., Bentley R.C., Krigman H., Silverberg S.G., Norris H.J., and Zaino R.J. Synoptic reports in gynecologic pathology. Int J Gynecol Pathol 13 (1994) 161-174
11. Pritts E.A. Fibroids and infertility: a systematic review of the evidence. Obstet Gynecol Surv 56 (2001) 483-491
12. Sheiner E., Bashiri A., Levy A., Hershkovitz R., Katz M., and Mazor M. Obstetric characteristics and perinatal outcome of pregnancies with uterine leiomyomas. J Reprod Med 49 (2004) 182-186
13. Walker C.L., and Stewart E.A. Uterine fibroids: the elephant in the room. Science 308 (2005) 1589-1592
14. Myers E.R., Barber M.D., Gustilo-Ashby T., Couchman G., Matchar D.B., and McCrory D.C. Management of uterine leiomyomata: what do we really know?. Obstet Gynecol 100 (2002) 8-17
15. Stewart E.A., Gedroyc W.M., Tempany C.M., Quade B.J., Inbar Y., Ehrenstein T., et al. Focused ultrasound treatment of uterine fibroid tumors: safety and feasibility of a noninvasive thermoablative technique. Am J Obstet Gynecol 189 (2003) 48-54
16. Hill A.B. The environment and disease: association or causation?. Proc R Soc Med 58 (1965) 295-300
17. Wegienka G., Baird D.D., Hertz-Picciotto I., Harlow S.D., Steege J.F., Hill M.C., et al. Self-reported heavy bleeding associated with uterine leiomyomata. Obstet Gynecol 101 (2003) 431-437
18. DeWaay D.J., Syrop C.H., Nygaard I.E., Davis W.A., and Van Voorhis B.J. Natural history of uterine polyps and leiomyomata. Obstet Gynecol 100 (2002) 3-7
19. Chen C.R., Buck G.M., Courey N.G., Perez K.M., and Wactawski-Wende J. Risk factors for uterine fibroids among women undergoing tubal sterilization. Am J Epidemiol 153 (2001) 20-26
20. Day Baird D., Dunson D.B., Hill M.C., Cousins D., and Schectman J.M. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 188 (2003) 100-107
21. Schwartz S., Voigt L., Tickman E., Yarbro P., Daling J., and Scholes D. Familial aggregation of uterine leiomyomata (2000) Presented at the annual meeting of the Society for Epidemiological Research, Seattle, WA, June
22. Treloar S.A., Martin N.G., Dennerstein L., Raphael B., and Heath A.C. Pathways to hysterectomy: insights from longitudinal twin research. Am J Obstet Gynecol 167 (1992) 82-88
23. Toro J.R., Nickerson M.L., Wei M.H., Warren M.B., Glenn G.M., Turner M.L., et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 73 (2003) 95-106
24. Touyz R.M., Cruzado M., Tabet F., Yao G., Salomon S., and Schiffrin E.L. Redox-dependent MAP kinase signaling by Ang II in vascular smooth muscle cells: role of receptor tyrosine kinase transactivation. Can J Physiol Pharmacol 81 (2003) 159-167
25. Myers E.R.B.M., Couchman G.M., Datta S., Gray R.N., Gustilo-Ashby T., et al. Management of uterine fibroids (Evidence Report/Technology Assessment) (No. 34, contract 290-97-0014 to the Duke Evidence-Based Practice Center). AHRQ Publication No. 01-E052 (2001), Agency for Healthcare Research and Quality, July, Rockville, MD
26. Marchionni M., Fambrini M., Zambelli V., Scarselli G., and Susini T. Reproductive performance before and after abdominal myomectomy: a retrospective analysis. Fertil Steril 82 (2004) 154-159 quiz 265
27. Hindley J., Gedroyc W.M., Regan L., Stewart E., Tempany C., Hynyen K., et al. MRI guidance of focused ultrasound therapy of uterine fibroids: early results. AJR Am J Roentgenol 183 (2004) 1713-1719
28. Chwalisz K., Perez M.C., Demanno D., Winkel C., Schubert G., and Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 26 (2005) 423-438
29. Spies J.B., Coyne K., Guaou Guaou N., Boyle D., Skyrnarz-Murphy K., and Gonzalves S.M. The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol 99 (2002) 290-300
30. Catherino W.H., Leppert P.C., Stenmark M.H., Payson M., Potlog-Nahari C., Nieman L.K., et al. Reduced dermatopontin expression is a molecular link between uterine leiomyomas and keloids. Genes Chromosomes Cancer 40 (2004) 204-217
31. Leppert P.C., Baginski T., Prupas C., Catherino W.H., Pletcher S., and Segars J.H. Comparative ultrastructure of collagen fibrils in uterine leiomyomas and normal myometrium. Fertil Steril 82 Suppl 3 (2004) 1182-1187
32. Shozu M., Sumitani H., Segawa T., Yang H.J., Murakami K., Kasai T., et al. Overexpression of aromatase P450 in leiomyoma tissue is driven primarily through promoter I.4 of the aromatase P450 gene (CYP19). J Clin Endocrinol Metab 87 (2002) 2540-2548